Progyny (PGNY) | Financial Analysis & Statements
Progyny Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
318.4M
Gross Profit
76.9M
24.15%
Operating Income
15.2M
4.78%
Net Income
12.5M
3.92%
EPS (Diluted)
$0.14
Balance Sheet Metrics
Total Assets
742.4M
Total Liabilities
226.4M
Shareholders Equity
516.0M
Debt to Equity
0.44
Cash Flow Metrics
Operating Cash Flow
59.4M
Free Cash Flow
48.6M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Progyny Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.3B | 1.2B | 1.1B | 786.9M | 500.6M |
| Cost of Goods Sold | 984.2M | 913.9M | 849.8M | 619.6M | 388.5M |
| Gross Profit | 304.5M | 253.4M | 238.8M | 167.3M | 112.1M |
| Gross Margin % | 23.6% | 21.7% | 21.9% | 21.3% | 22.4% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 219.2M | 185.9M | 176.6M | 144.0M | 79.8M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 219.2M | 185.9M | 176.6M | 144.0M | 79.8M |
| Operating Income | 85.3M | 67.5M | 62.2M | 23.3M | 32.3M |
| Operating Margin % | 6.6% | 5.8% | 5.7% | 3.0% | 6.5% |
| Non-Operating Items | |||||
| Interest Income | 10.2M | 15.7M | - | - | - |
| Interest Expense | - | - | - | - | - |
| Other Non-Operating Income | - | - | 5.2M | 286.0K | -366.0K |
| Pre-tax Income | 95.4M | 83.2M | 70.7M | 24.4M | 32.4M |
| Income Tax | 36.9M | 28.9M | 8.7M | -5.9M | -33.3M |
| Effective Tax Rate % | 38.7% | 34.7% | 12.2% | -24.2% | -102.8% |
| Net Income | 58.5M | 54.3M | 62.0M | 30.4M | 65.8M |
| Net Margin % | 4.5% | 4.7% | 5.7% | 3.9% | 13.1% |
| Key Metrics | |||||
| EBITDA | 90.2M | 70.6M | 64.5M | 24.9M | 33.6M |
| EPS (Basic) | $0.68 | $0.59 | $0.65 | $0.33 | $0.74 |
| EPS (Diluted) | $0.65 | $0.57 | $0.62 | $0.30 | $0.66 |
| Basic Shares Outstanding | 85651721 | 91481995 | 95021175 | 92195068 | 89105562 |
| Diluted Shares Outstanding | 85651721 | 91481995 | 95021175 | 92195068 | 89105562 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Progyny Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 112.2M | 162.3M | 97.3M | 120.1M | 91.4M |
| Short-term Investments | 197.9M | 65.6M | 273.8M | 69.2M | 28.0M |
| Accounts Receivable | 220.3M | 235.3M | 241.9M | 240.1M | 134.6M |
| Inventory | - | - | - | - | - |
| Other Current Assets | 21.4M | 9.4M | 27.5M | 4.5M | 4.6M |
| Total Current Assets | 551.8M | 472.7M | 640.4M | 433.9M | 258.5M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 25.0M | 17.3M | 17.6M | 6.9M | 7.8M |
| Goodwill | 46.2M | 32.4M | 23.8M | 23.9M | 24.4M |
| Intangible Assets | 6.2M | 1.3M | - | 99.0K | 599.0K |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 109.5M | 87.9M | 76.5M | 81.9M | 74.2M |
| Total Non-Current Assets | 190.7M | 134.4M | 116.2M | 109.1M | 99.5M |
| Total Assets | 742.4M | 607.1M | 756.6M | 543.0M | 358.1M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 124.1M | 95.1M | 125.4M | 109.3M | 61.4M |
| Short-term Debt | 3.7M | 2.9M | 2.1M | 1.2M | 1.2M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 1.9M | 5.3M | 1.2M | 1.2M | 2.2M |
| Total Current Liabilities | 202.4M | 168.6M | 186.0M | 159.5M | 98.8M |
| Non-Current Liabilities | |||||
| Long-term Debt | 24.0M | 16.4M | 17.2M | 6.5M | 7.4M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 24.0M | 16.4M | 17.2M | 6.5M | 7.4M |
| Total Liabilities | 226.4M | 185.0M | 203.2M | 166.0M | 106.2M |
| Equity | |||||
| Common Stock | 9.0K | 9.0K | 9.0K | 9.0K | 9.0K |
| Retained Earnings | 202.8M | 144.3M | 90.0M | 27.9M | -2.4M |
| Treasury Stock | 388.1M | 303.9M | 1.0M | 1.0M | 1.0M |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 516.0M | 422.1M | 553.4M | 377.0M | 251.8M |
| Key Metrics | |||||
| Total Debt | 27.7M | 19.3M | 19.4M | 7.7M | 8.6M |
| Working Capital | 349.4M | 304.1M | 454.5M | 274.3M | 159.7M |
Balance Sheet Composition
Progyny Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 58.5M | 54.3M | 62.0M | 30.4M | 65.8M |
| Depreciation & Amortization | 4.9M | 3.2M | 2.3M | 1.6M | 1.3M |
| Stock-Based Compensation | 131.9M | 128.1M | 122.6M | 100.7M | 33.7M |
| Working Capital Changes | 14.3M | -39.7M | -4.9M | -72.7M | -54.1M |
| Operating Cash Flow | 202.0M | 135.5M | 185.8M | 53.4M | 13.4M |
| Investing Activities | |||||
| Capital Expenditures | -18.4M | -5.4M | -3.6M | -3.2M | -2.1M |
| Acquisitions | -9.3M | -5.3M | - | - | - |
| Investment Purchases | -355.0M | -170.3M | -429.7M | -163.3M | -111.5M |
| Investment Sales | 223.7M | 376.8M | 232.8M | 122.7M | 122.4M |
| Investing Cash Flow | -159.0M | 195.8M | -200.5M | -43.9M | 8.8M |
| Financing Activities | |||||
| Share Repurchases | -81.7M | -300.3M | - | - | 0 |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | 0 |
| Financing Cash Flow | -100.6M | -312.3M | -17.2M | -12.1M | -18.0M |
| Free Cash Flow | 191.8M | 173.7M | 185.2M | 77.2M | 23.9M |
| Net Change in Cash | -57.6M | 19.0M | -31.9M | -2.6M | 4.2M |
Cash Flow Trend
Progyny Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
27.18
Forward P/E
8.41
Price to Book
2.83
Price to Sales
1.12
PEG Ratio
1.09
Profitability Ratios
Profit Margin
4.54%
Operating Margin
7.20%
Return on Equity
12.48%
Return on Assets
8.61%
Financial Health
Current Ratio
2.73
Debt to Equity
5.37
Beta
0.99
Per Share Data
EPS (TTM)
$0.65
Book Value per Share
$6.24
Revenue per Share
$15.05
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| PGNY | 1.4B | 27.18 | 2.83 | 12.48% | 4.54% | 5.37 |
| UnitedHealth | 322.3B | 26.81 | 3.42 | 12.18% | 2.68% | 73.98 |
| CVS Health | 101.1B | 55.65 | 1.31 | 2.29% | 0.44% | 106.06 |
| Clover Health | 1.3B | -14.09 | 4.20 | -26.33% | -4.45% | 0.00 |
| Elevance Health | 76.4B | 13.19 | 1.67 | 13.25% | 2.84% | 74.39 |
| Cigna | 72.7B | 12.61 | 1.77 | 15.13% | 2.17% | 75.14 |
Financial data is updated regularly. All figures are in the company's reporting currency.






